Literature DB >> 9934799

Successful chemotherapy in a patient with recurrent carcinoma of the urachus.

O Ichiyanagi1, I Sasagawa, Y Suzuki, Y Iijima, Y Kubota, T Nakada, S Arai.   

Abstract

Urachal neoplasm generally has a poor prognosis, because of long latency period, extravesical progression and pathological predominant pattern of adenocarcinomas. We report a case of recurrent poorly differentiated carcinoma of urachal remnant, which responded well to combination systemic chemotherapy (methotrexate, vinblastine, doxorubicin and cisplatin: M-VAC). Our case was possibly of transitional cell origin. The patient has been symptom-free even 13 months after the first chemotherapy course.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9934799     DOI： 10.1007/bf02550547

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  7 in total

1.  Invasive adenocarcinoma of bladder response to cisplatinum, methotrexate, and vinblastine chemotherapy.

Authors:  T G Bavendam; E V Kramolowsky; F A Mitros
Journal:  Urology       Date:  1989-01       Impact factor: 2.649

2.  Carcinoma of the urachus in an adolescent: a case report.

Authors:  L F Rankin; G D Allen; F R Yuppa; M J Pirozzi; J R Hajjar
Journal:  J Urol       Date:  1993-11       Impact factor: 7.450

3.  Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.

Authors:  C N Sternberg; A Yagoda; H I Scher; R C Watson; T Ahmed; L R Weiselberg; N Geller; P S Hollander; H W Herr; P C Sogani
Journal:  J Urol       Date:  1985-03       Impact factor: 7.450

4.  Carcinoma of the urachus.

Authors:  C Cornil; C T Reynolds; C J Kickham
Journal:  J Urol       Date:  1967-07       Impact factor: 7.450

5.  Primary adenocarcinoma of the bladder: a retrospective study of 20 patients.

Authors:  E Jacobo; S Loening; J D Schmidt; D A Culp
Journal:  J Urol       Date:  1977-01       Impact factor: 7.450

Review 6.  Malignant urachal lesions.

Authors:  C A Sheldon; R V Clayman; R Gonzalez; R D Williams; E E Fraley
Journal:  J Urol       Date:  1984-01       Impact factor: 7.450

7.  Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C.

Authors:  C J Logothetis; M L Samuels; S Ogden
Journal:  Urology       Date:  1985-09       Impact factor: 2.649
  7 in total
  4 in total

1.  Non-invasive, low-grade papillary urothelial carcinoma in the urachus.

Authors:  Gyrithe Lynghøj Pedersen; Claus Dahl; Nessn Htum Azawi
Journal:  BMJ Case Rep       Date:  2013-11-27

2.  Treatment of metastatic urachal adenocarcinoma in a young woman: a case report.

Authors:  Elmehdi Tazi; Issam Lalya; Mohammed Fadl Tazi; Youness Ahallal; Hind M'rabti; Hassan Errihani
Journal:  Cases J       Date:  2009-12-04

Review 3.  Surgical and chemotherapeutic experience regarding a urachal carcinoma with repeated relapse: case report and literature review.

Authors:  Liang Zong; Ping Chen
Journal:  World J Surg Oncol       Date:  2013-08-01       Impact factor: 2.754

Review 4.  Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Authors:  Henning Reis; Ulrich Krafft; Christian Niedworok; Orsolya Módos; Thomas Herold; Mark Behrendt; Hikmat Al-Ahmadie; Boris Hadaschik; Peter Nyirady; Tibor Szarvas
Journal:  Dis Markers       Date:  2018-03-12       Impact factor: 3.434
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.